Introduction
growth hormone [15, 16, 24] .
Only the free IGF-1 appears to be biologically active Insulin-like growth factor 1 (IGF-1) is a polypeptide in serum, and the IGFBPs have been proposed as both (molecular weight~7650 Daltons) that has been reservoirs and regulators of IGF-1 bioactivity. The shown to increase renal blood flow (RBF ) and glomeractions of IGFBPs are not well understood. Under ular filtration rate (GFR) [1] [2] [3] , stimulate renal hypersome experimental conditions, IGFBPs may enhance trophy [4] [5] [6] , enhance recovery of renal function in the actions of IGF-1 on tissues. IGF-1 acts primarily animals with experimental acute renal failure [7] [8] [9] [10] [11] [12] [13] , through binding to the IGF-1 receptor which activates and promote anabolism [7] . As a result of these the tyrosine kinase system [25, 26 ] . IGF-1 in pharmacoproperties, IGF-1 has elicited substantial interest as a logical concentrations may also crossreact with the possible therapeutic agent. This paper will briefly insulin receptor, but the affinity of the insulin receptor review the physiology of IGF-1 and summarize the for insulin is~1000 times greater than for IGF-1 [27] . evidence substantiating the potential uses for IGF-1 in Similarly, the IGF-1 receptor has roughly 1000 times patients with acute or chronic renal failure (CRF ).
more affinity for IGF-1 than for insulin [27] . There is less evidence to indicate a possible therapeutic IGF-1 appears to mediate most but not all of the role for IGF-2, another growth factor identified in physiological effects of growth hormone [14] . IGF-1 plasma and tissues [14] . A discussion of IGF-2 is has many insulin-like effects and promotes a number beyond the scope of this paper.
of anabolic processes including the following: (i) lowers blood glucose by enhancing uptake of glucose by skeletal and myocardial muscle and adipocytes, and
Physiology of IGF-1
suppresses hepatic glucose production by decreasing gluconeogenesis and glycogenolysis [14, 28, 29] . IGF-1 IGF-1 is secreted by many cells. Hepatic secretion is only~7% as potent as insulin as a hypoglyappears to be the primary source of serum IGF-1 [14] . caemic agent; (ii) stimulates amino acid transport; In serum, IGF-1 is almost entirely bound to IGF (iii) enhances protein synthesis and suppresses protein binding proteins (IGFBPs) [15, 16 ] . Six IGFBPs have degradation in many tissues [14, 30, 31] ; (iv) stimulates been identified. The most abundant IGFBP in serum renal synthesis of 1,25-dihydroxycholecalciferol [32] is IGFBP-3. Serum IGFBPs 1, 2, and 4 are less and renal tubular reabsorption of phosphate [33, 34] abundant, and IGFBPs 5 and 6 are virtually undetect-and possibly sodium; (v) enhances replication and bone able in serum [15, 16 ] . The relative abundances of the collagen synthesis by osteoblasts [35] , and bone formaIGFBPs in solid tissues are different from sera and tion [36 ] ; (vi) promotes cell hypertrophy and hyperplaalso vary according to the tissue. Many factors affect sia; (vii) increases RBF and GFR [1] [2] [3] and causes serum IGF-1 and IGFBPs. Growth hormone is the renal hypertrophy [15]; (viii) increases total body most powerful stimulus for IGF-1 secretion [17] . growth and enlargement of certain organs including Fasting, malnutrition, low intakes of protein or cal-bone, kidney, thymus and spleen [37, 38] ; (ix) reduces ories, severe sepsis and insulin suppress serum IGF-1 weight loss during starvation [39] , and (x) enhances [18, 19] . Growth hormone, insulin, IGF-1 and fasting wound healing [40] . reduce serum IGFBP-1 [20] [21] [22] [23] , and IGF-1 elevates serum IGFBP-2 [15,16,24]; serum IGFBP-3 is Insulin-like growth factor 1 and renal failure 35 tomedin C as it was then called) are usually normal tyrosine kinase from the skeletal muscle of the CRF and pair-fed, SO rats were similar. Under these condior near normal, the bioactivity of this hormone is reduced in uraemic sera [41] . Several mechanisms for tions, the phosphorylation of exogenous IRS-1 was still impaired in skeletal muscle of the CRF rats. This finding resistance to IGF-1 have been identified. These include the following.
suggests that this reduced phosphorylation of exogenous IRS-1 in the CRF rats may be a separate defect from (i) Increased plasma concentrations of two classes of the impaired phosphorylation of the tyrosine kinase in compounds: sufficiently small to be haemodialysed the b-subunit of the IGF-1 receptor in these animals. [41] or too large [42] for effective removal by Thus, in skeletal muscle of CRF rats, as compared haemodialysis.
to pair-fed, SO controls, there is (i) resistance to IGF-1, (ii) Impaired phosphorylation of tyrosine kinase in (ii) up-regulation of the IGF-1 receptor number, the b-subunit of the IGF-1 receptor in skeletal (iii) normal structure and binding affinity to ligands in muscle of rats with CRF [31] . the ligand-binding domain (the a-subunit) of the IGF-1 (iii) Impaired phosphorylation of insulin receptor sub-receptor, (iv) impaired activation of the intrinsic recepstrate 1 (IRS-1) by tyrosine kinase in the IGF-1 tor tyrosine kinase domain (the b-subunit) of the IGF-1 receptor in skeletal muscle [31] . receptor, and (v) decreased phosphorylation of IRS-1 (iv) Elevated basal cytosolic calcium [Ca2+] i in cardi-by this tyrosine kinase domain. omyocytes of rats with CRF and a reduced increase Studies of other investigators indicate that in rats in [Ca2+] i in response to IGF-1 stimulation [43] . with CRF, the basal cytosolic calcium ([Ca2+] i ) is increased in a number of different tissues, including We examined the mechanisms of action and causes for resistance to IGF-1 in skeletal muscle in CRF. Rats heart [44, 45] . Moreover, the increment in cytosolic calcium in response to stimuli is impaired in these with CRF and sham-operated, pair-fed control (SO) rats were studied [31] . The rats were given NaHCO 3 to animals, and this is associated with a reduction in the effector response to various stimuli by these cells. Since prevent acidaemia. After 21 days of pair-feeding, rats were killed, and the dose-response effects of IGF-1 on IGF-1 also stimulates an increase in cytosolic calcium [46, 47] , we hypothesized that resistance to IGF-1 in muscle protein synthesis and degradation were determined. As compared to SO rats, the CRF rats had CRF rats might also be caused by elevation of basal
[Ca2+] i . enhanced protein degradation and suppressed protein synthesis in the epitrochlearis muscle (P<0.01 vs SO We examined this question in cardiomyocytes from CRF rats in the following experiment [43] . Spraguerats). When the epitrochlearis muscle was incubated with recombinant human IGF-1 (rhIGF-1), both the Dawley rats were randomly assigned to one of four groups; CRF, CRF with parathyroidectomy (PTX ), rhIGF-1 induced reduction in protein degradation and increase in protein synthesis were suppressed in the CRF with felodipine (F, a calcium channel blocker) added daily to the drinking water, and sham-operated CRF rats as compared to the SO animals (P<0.01 vs SO rats), indicating resistance to rhIGF-1 in CRF rats. (SO) controls. Each group contained seven or eight rats. The CRF-PTX and CRF-F groups were examined Serum and skeletal muscle IGF-1 and muscle IGF-1 mRNA were reduced in CRF rats as compared to pair-because PTX and calcium channel blockers are known to decrease basal [Ca2+] i in CRF rats [44] . Rats from fed, SO rats. In CRF rats, skeletal muscle IGF receptor mRNA was increased. Ligand binding assays and dis-each group were fed the same diet for 20-22 days, and three groups of rats were pair-fed to the CRF animals. placement binding studies indicated that the CRF rats displayed an increase in the IGF-1 receptor number The CRF-PTX rats were also given calcium in drinking water. Basal [Ca2+] i in cardiomyocytes was significantly with a normal receptor binding affinity. Affinity labelling studies also indicated that the a-subunit of the muscle increased in the CRF rats (CRF rats vs each other group, P<0.05) and was not different from SO control IGF-1 receptor was not different in either the M r or the binding affinity to IGF-1 or insulin in the CRF rats as values in the CRF-PTX and CRF-F animals. When the cardiomyocytes were incubated for 120 min with compared to SO animals. However, in CRF rats, the rhIGF-1-induced autophosphorylation of the IGF-1 50, 100, 200 or 400 mg/ml of rhIGF-1, the increment in [Ca2+] i above basal levels was markedly impaired receptor b-subunit was markedly suppressed, and the in vitro tyrosine kinase activity of the partially purified only in the CRF rats as compared to the pair-fed, SO rats, whereas the increment in [Ca2+] i in the CRF-PTX IGF-1 receptor b-subunit towards exogenous IRS-1, a natural substrate for the IGF-1 receptor tyrosine kinase, and CRF-F rats was not different from that of the SO rats. The maximum [Ca2+] i after rhIGF-1 stimulation was significantly reduced [31] .
The tyrosine kinase activity of the b-subunit of was similar in all four groups. Incorporation of [14C]-leucine into cardiomyocyte proteins without rhIGF-1 the IGF-1 receptor phosphorylates IRS-1. Therefore, the reduced phosphorylation of exogenous IRS-1 in the added and after incubation with the foregoing concentrations of rhIGF-1 was significantly decreased in the CRF rats could be solely due to the impaired tyrosine kinase activity of the b-subunit. To examine this possibil-CRF, CRF-PTX and CRF-F rats as compared to the SO rats (P<0.05). However, the [14C ]leucine incorpity, in another experiment [31] , a greater quantity of the partially purified b-subunit of the IGF-1 receptor oration into the cardiomyocyte proteins in the CRF-PTX and CRF-F rats was also significantly greater from the CRF rats was admixed with exogenous IRS-1 so that the amounts of radiolabelled phosphorylated than in the CRF rats. These data suggest that in myocardial cells of CRF rats:
is larger dose of rhIGF-1. The decrease in plasma insulin, C-peptide, and concentrations of many of the amino elevated, (ii) rhIGF-1 stimulation of protein synthesis is impaired; (iii) PTX or the calcium channel blocker acids was less, and the reduction in plasma glucose was similar in the MHD and CAPD patients as comfelodipine reduces basal [Ca2+] i to the levels in the SO rats and increases the rhIGF-1 induced rise in [Ca2+] i pared to the normal individuals. With the 50 mg rhIGF-1/kg dose, plasma insulin and C-peptide fell to the control levels; (iv) PTX and the calcium channel blocker increase the rhIGF-1 induced stimulation of more rapidly and often to a greater magnitude in the normal subjects as compared to the MHD and CAPD protein synthesis, although not to the levels of the pair-fed, SO rats; and (v) the impaired response to patients. For some of these compounds, there was no significant decrease in plasma levels with the 50 mg IGF-1 appears to be caused at least partly by the elevation in the basal [Ca2+] i . rhIGF-1/kg dose in the MHD or CAPD patients during the 4 h of observation.
With the 100 mg rhIGF-1/kg dose, plasma insulin,
Pharmacokinetics and anabolic effects of IGF-1 in
C-peptide and amino acids decreased almost as fre-
patients with CRF
quently in the MHD and CAPD patients as in the normal individuals, but the magnitude of the reduction was often significantly less in the two chronic dialysis In order to treat patients receiving maintenance haemodialysis (MHD) or individuals undergoing chronic groups [50] . This impaired response occurred in both the MHD and CAPD patients even though with the peritoneal dialysis with rhIGF-1, it was first necessary to establish whether the pharmacokinetics of rhIGF-1 100 mg rhIGF-1/kg dose, their plasma IGF-1 concentrations were significantly greater than in the normals are altered in these individuals. We examined this question in three groups of adults: MHD patients, during most of the first 4 h after the rhIGF-1 injection (see above). These observations provide the first in vivo continuous ambulatory peritoneal dialysis (CAPD) patients and normal individuals [48] . Each subject evidence for resistance to the metabolic actions of rhIGF-1 in patients with advanced CRF. was given a subcutaneous injection of rhIGF-1 on two separate days. One injection provided 50 mg Notwithstanding this evidence for resistance to IGF-1, the MHD and CAPD patients did respond to rhIGF-1/kg body weight and the other injection 100 mg rhIGF-1/kg. Blood was drawn serially after each rhIGF-1, particularly at the 100 mg/kg dose. We therefore examined whether rhIGF-1 could induce an anarhIGF-1 injection. Individuals were fasted from the night before the study until after the 4-h blood drawing bolic response in maintenance dialysis patients who had protein-energy malnutrition [51] . Patients undergoing after the injection. After the subcutaneous dose of 50 mg/kg of rhIGF-1, the pharmacokinetics of serum MHD or chronic peritoneal dialysis frequently are malnourished. Although there are many causes for IGF-1 in the MHD and CAPD patients were not different from normal. With a subcutaneous dose of protein-energy malnutrition in maintenance dialysis patients, inadequate intake of nutrients is probably one 100 mg/kg, peak serum IGF-1 concentrations were significantly greater in the MHD (1015±86 SEM mg/l ) of the most common and decisive contributors to this condition. Prescription of greater food intakes usually and CAPD (1049±156 mg/l ) patients in comparison to the normal adults (637±85 mg/l ) [48] . Also, the does not correct this problem. Thus, we asked whether in malnourished patients ingesting their typical diets, half-life and volume of distribution of IGF-1 were significantly decreased in both the MHD and CAPD rhIGF-1 injections would improve nitrogen balance.
Six CAPD patients with protein or calorie malnutripatients. The T max∞ area under the curve and serum clearance of IGF-1 were not different in the three tion were admitted to the Clinical Research Center at Harbor-UCLA Medical Center for 35 days [51]. groups. The foregoing alterations in serum IGF-1 concentrations were transient. By 12-14 h after the Patients were fed a constant diet providing 26±2 kcal/kg/day and 1.03±0.09 g protein/kg/day and injection, serum IGF-1 levels were not different among the MHD patients, CAPD patients and normal indi-received a constant CAPD regimen throughout the study. After the first three 5-day baseline periods, viduals. These findings are similar to the results of other studies of rhIGF-1 kinetics in patients with patients were given subcutaneous injections of rhIGF-1, 50 or 100 mg/kg every 12 h, for the next four 5-day advanced CRF [49] and indicate that the dosage of rhIGF-1 does not need to be modified in patients with periods. Serum urea nitrogen (SUN ) decreased from 68±12.5 to 54±8 mg/dl during the baseline periods CRF because of altered pharmacokinetics.
In vivo studies of patients with CRF support the (P<0.07) and was significantly lower, 40±6 mg/dl, at the end of the treatment periods (P=0.05). After thesis that they display resistance to the actions of IGF-1. In the pharmacokinetic study described above, equilibration, nitrogen balance, adjusted for estimated changes in body urea nitrogen and unmeasured losses, blood was obtained before the injection of rhIGF-1 and serially for 4 h afterwards for measurement of became significantly more positive during rhIGF-1 treatment (baseline vs treatment, P<0.001). Nitrogen other compounds [50] . After the rhIGF-1 injection, there was a reduction in plasma insulin, C-peptide, balance during baseline was not different from zero and was strongly positive during rhIGF-1 treatment cortisol, most amino acids, and glucose in the normal individuals. In all three groups of subjects, the magni-(P<0.001). The major cause for improved nitrogen balance was reduced dialysate nitrogen. These data tude of the decrease tended to be greater with the Insulin-like growth factor 1 and renal failure 37 indicate that rhIGF-1 may increase protein balance in [56, 57] . However, mice transgenic for IGF-1 who have serum IGF-1 levels similar to that present in the mice stable, malnourished CAPD patients who are ingesting marginally adequate or submarginal diets. Further transgenic for growth hormone appear less likely to develop glomerulosclerosis [56, 57] . Children with CRF studies will be necessary to assess whether long-term treatment of CAPD patients with protein-energy mal-who are given regular growth hormone injections do not appear to have a more rapid loss of renal function nutrition will improve body composition, clinical status, rehabilitation or mortality rates.
[58]. Also, adult patients with chronic acromegaly have increased glomerular filtration rates and renal hypertrophy but do not develop progressive renal
Effects of IGF-1 on renal function in patients with
failure [59, 60] . Further monitoring of patients treated
CRF
chronically with IGF-1 will be necessary to determine whether this hormone will maintain a sustained increase in the glomerular filtration rate without pro-IGF-1 increases renal blood flow and glomerular filtration rate in the normal kidney of rats and humans moting glomerulosclerosis or progressive renal damage. 
Role of IGF-1 in acute renal failure
and coworkers administered rhIGF-1 to patients with advanced CRF to assess whether their renal function can be increased and thereby decrease uraemic symp-Early during the investigation of the potential therapeutic actions of IGF-1, it was hypothesized that toms and postpone the need for maintenance dialysis therapy or renal transplantation [53, 54] . In one study, IGF-1 might accelerate the rate of recovery from acute renal failure. Interest in this possibility was stimulated four CRF patients with a GFR of 22-55 ml/min/1.73 m2 given rhIGF-1, 100 mg/kg twice-daily for 4 days, showed by the following observations: (i) IGF-1 stimulates hypertrophy or mitosis of a number of renal cell types an increase in inulin and para-aminohippurate (PAH ) clearances and kidney volume [53] . In a second [4-6,15]; (ii) IGF-1 receptors are present in the glomerulus and proximal tubules [15] ; (iii) IGF-1 is synthestudy, patients with more advanced CRF (baseline inulin clearances less than 21 ml/min/1.73 m2) were sized in the glomerulus and collecting ducts of certain animals [15] ; (iv) In normal rats and humans, rhIGF-1 given rhIGF-1, 100 mg/kg, twice-daily for 4 days (four patients) or for 13-27 days (five patients) [54] . In the acutely increases renal blood flow and glomerular filtration rate [1] [2] [3] 52] ; these actions are probably short term four day studies, inulin and PAH clearances were increased with rhIGF-1 treatment, but kidney mediated by nitric oxide [61] .
Several studies [7-13] have now examined whether volume did not change. In the longer term studies, there was no sustained increase in inulin clearance, and PAH rhIGF-1 will enhance recovery from experimental acute renal failure (ARF ). The results indicate that in rats, clearance also rose transiently. Moreover, a number of patients developed symptoms associated with rhIGF-1 rhIGF-1 will accelerate recovery from ARF caused by ischaemia [7] [8] [9] [10] [11] or mercuric chloride toxicity [12,13] injections, most commonly jaw pain or nasal congestion, which caused rhIGF-1 treatment to be discontinued but possibly not when ARF is caused by radiocontrast media [62] . rhIGF-1 was observed to accelerate the prematurely in four of the five patients. In addition, serum IGFBP-3, the major binding protein for IGF-1 recovery of renal function even when the rhIGF-1 injections were not commenced until as long as 5 or in serum, declined during rhIGF-1 treatment. These investigators questioned whether the refractoriness to 24 h [7,13] after the onset of ARF. rhIGF-1 also reduces net protein breakdown in rats with ischaemic rhIGF-1 in these patients might be caused by the reduction in serum IGFBP-3 [54].
ARF; this effect is associated with a suppression of protein degradation and enhanced protein synthesis in Therefore, this research team carried out another study in five patients with advanced CRF who were skeletal muscle [7] .
There appear to be at least two mechanisms by treated intermittently with low doses of rhIGF-1 (50 mg/kg/day) subcutaneously for up to 7 months which rhIGF-1 increases renal function in rats with ARF. First, rhIGF-1 stimulates replication of new cells [55] . rhIGF-1 was given daily for cycles of 4 days followed by three consecutive days without hormone in the proximal renal tubules and elsewhere in the kidney [7, 8, 12] . However, rhIGF-1 probably also injections. Serum IGF-1 and IGFBP-2 increased during the IGF-1 treatment, and serum IGFBP-3 did not acutely increases renal blood flow and glomerular filtration rate in ARF [7, 8] by haemodynamic effects. change. Inulin clearances increased by 42-81% during the first 24 days of treatment, and PAH clearances also These haemodynamic effects of rhIGF-1 may be mediated by nitric oxide [9,61,63]. increased. In one patient treated for 7 months, the inulin clearance remained elevated. Side effects associEvidence for an haemodynamic effect on the recovery of renal function is inferential and based upon the ated with the rhIGF-1 therapy were mild.
A potential concern with the long term use of following observations. As indicated above, rhIGF-1 increases renal blood flow and the glomerular filtration rhIGF-1 to treat CRF patients is the possibility that the IGF-1 might induce glomerulosclerosis. Rats with rate in the normal kidney [1] [2] [3] 52] and the chronically and severely damaged kidney [53] [54] [55] . Rats with increased growth hormone levels and mice transgenic for growth hormone develop glomerulosclerosis ischaemic ARF that receive rhIGF-1 injections may increase urine nitric oxide excretion [9, 63] 
